GlassScriptPhysician profile
James J Zumpano
NPI 1437141363
$2,194.91
in general payments reported to CMS, 2019-2025
26 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $219 · 2021: $119 · 2022: $325 · 2023: $490 · 2024: $398 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.16 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $312.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $259.71 | 2019-2025 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.25 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $164.44 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $159.53 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $146.09 | 2019-2023 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.41 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $125.70 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $113.39 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $91.00 | 2019-2023 | |
| Abbvie INC. | $67.50 | 2023-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $59.94 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $40.19 | 2019-2022 | |
| Amgen INC. | $38.07 | 2025 | Repatha, Otezla |
| Neurocrine Biosciences, INC. | $36.52 | 2023 | Ingrezza, Ongentys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $35.78 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $31.76 | 2023 | Austedo Xr, Austedo |
| Amarin Pharma, INC. | $28.03 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $19.96 | 2022 | |
| Scilex Pharmaceuticals INC. | $18.72 | 2019 | |
| Daiichi Sankyo INC. | $18.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.43 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.25 | 2019 | |
| Seqirus USA INC | $13.89 | 2024 | Flucelvax, Fluad |
| Eisai INC. | $12.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zumpano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.